Kent Hawryluk
President & CEO
Kent Hawryluk is a Co-Founder of, and currently serves as President and Chief Executive Officer of, MBX Biosciences, Inc. (Nasdaq: MBX), roles he has held since January 2020. He also has served as a member of MBX’s Board of Directors since April 2019.
Prior to joining MBX, Mr. Hawryluk was Co-Founder and Chief Business Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), an RNA therapeutics company, from January 2013 to December 2019.
Previously, he served as Co-Founder and Chief Executive Officer of MB2 LLC (subsequently acquired by Novo Nordisk Inc.), a clinical-stage company focused on diabetes and obesity, from May 2014 to March 2016. Mr. Hawryluk co-founded Marcadia Biotech Inc. (subsequently acquired by F. Hoffmann-La Roche AG) and served as its Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. Mr. Hawryluk served as a director of Gemphire Therapeutics Inc. (Nasdaq: GEMP), a clinical-stage cardiovascular drug company, from February 2015 to February 2019.
Mr. Hawryluk earned a B.A. from Princeton University, an MBA from the Kellogg School of Management at Northwestern University, and an M.S. in Biology from Purdue University.
Suffix
MBA
Sessions
-
10-Feb-2025Obesity: Next Medicines with Impact
)
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}